Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HK1 | P19367 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23760097 | 0.82 | GAA (0.46) | CYP3A4MAPTCA9PTGS2HPGD | |
| SCHEMBL11382490 | 0.81 | KDM4E (0.48) | MAPTHPGDALDH1A1KDM4EPKM | |
| SCHEMBL11393184 | 0.81 | HTT (0.41) | MAPTHPGDALDH1A1KDM4EAPOBEC3G | |
| SCHEMBL374491 | 0.79 | CYP3A4 (0.47) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL11383026 | 0.78 | PDE3B (0.41) | CYP3A4MAPTALDH1A1KDM4ETUBB4A | |
| SCHEMBL11383070 | 0.78 | ALDH1A1 (0.43) | MAPTPTGS2HPGDALDH1A1KDM4E | |
| SCHEMBL76835 | 0.78 | HTR3E (0.53) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL1119953 | 0.77 | NAAA (0.35) | TUBB1 | |
| SCHEMBL6179404 | 0.75 | P2RY6 (0.38) | CYP3A4MAPTPTGS2HPGDALDH1A1 | |
| SCHEMBL1021008 | 0.74 | ALDH1A1 (0.50) | CYP3A4MAPTCA9PTGS2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| CN-105267967-A | Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2016-01-27 | — | — | CN | claimed |
| CN-104415332-A | Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2015-03-18 | — | — | CN | claimed |
| CN-104117064-A | Combined application of isothiocyanate compound and hormone medicine | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2014-10-29 | — | — | CN | claimed |
| EP-3446689-B1 | ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA | JC WUXI COMPANY INC (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-118873522-A | Application of isothiocyanate compound | 无锡杰西医药股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118619952-A | Aloperine derivative, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-09-10 | — | — | CN | disclosed |
| CN-113262218-B | Use of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114540846-B | Synthesis method of 1,2, 4-triazolo six-membered nitrogen heterocycle-3-amine | 五邑大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-114516870-B | Triazolo hexa-nitrogen heterocyclic-3-amine compound and preparation method and application thereof | 五邑大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-113354592-B | 2-thioquinazolinone compound and preparation method and application thereof | 赣南师范大学 | 2022-06-21 | — | — | CN | disclosed |
| US-5246935-A | Cardiovascular and gastrointestinal | NOVO NORDISK A/S (DK) | 1993-09-21 | — | — | US | disclosed |
| EP-0544765-A1 | PIPERAZINYL DERIVATIVES. | NOVO NORDISK AS (DK) | 1993-06-09 | — | — | EP | disclosed |
| CN-1069490-A | Urea derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-03-03 | — | — | CN | disclosed |
| US-5190961-A | Bactericides | TERUMO KABUSHIKI KAISHA (JP) | 1993-03-02 | — | — | US | disclosed |
| WO-1992003426-A1 | PIPERAZINYL DERIVATIVES | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | disclosed |
| EP-0470006-A1 | Thiourea derivatives and antimicrobial agent and antiulcer agent containing the same | TERUMO KABUSHIKI KAISHA (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-4634660-A | ANTIFOGGING AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 1987-01-06 | — | — | US | disclosed |
| EP-0123146-A2 | Compound with antiinflammatory activity, process for preparation thereof and pharmaceutical compositions therefrom | CHIESI FARMACEUTICI S.p.A. (IT) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | ACHE 1947/4885CYP3A4 2452/4885MAPT 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.